|ISSUE 13 - April 1, 2016|
At a meeting of the NCI Board of Scientific Advisors March 29, NCI officials had good news to report:
• The appropriations are increasing, with bipartisan support to boot.
• The White House “moonshot” initiative on cancer is bringing new money and new urgency to the institute’s work.
The cancer program has seen many aggressive mandates and has made many big promises, and it's worthwhile to remember this current initiative is being launched by an administration that is concluding its term.
The Securities and Exchange Commission March 29 announced fraud charges against AVEO Pharmaceuticals Inc., a biotechnology company, and three of its former executives.
SEC said the company agreed to pay a $4 million penalty to settle the charges without admitting or denying the allegations.
The agency said it is continuing to pursue its case against three of AVEO’s former officers: CEO Tuan Ha-Ngoc, Chief Financial Officer David Johnston, and Chief Medical Officer William Slichenmyer.
Over 70 deans and directors of public health programs and institutes signed a letter March 21 asking the White House for to prioritize federal investments in public health and cancer prevention.
The letter, addressed to Vice President Joe Biden, urges the administration to “pay careful attention to the balance between treatment and prevention-related investments.”
|Drugs and Targets